Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Tests resistance exercise for people with brain cancer glioblastoma

Tests a circuit-based strength exercise program in adults with glioblastoma on active treatment.

Plain-language title generated from the registry record
Registry title: The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors

Key facts

Where
Halifax, CanadaSee the site

Where in Canada

  • QEII Health Sciences CentreHalifax, CanadaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Nova Scotia Health Authority
Trial code
NCT05116137
Record updated
29 May 2026
Original description
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise literature and explore the role of a tailored circuit-based resistance training program on functional fitness (i.e., ability to carry out tasks of daily living) and associated health outcomes (e.g., quality of life) for GBM patients on active treatment.Read full original descriptionShow less

The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors (RESIST)

Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise literature and explore the role of a tailored circuit-based resistance training program on functional fitness (i.e., ability to carry out tasks of daily living) and associated health outcomes (e.g., quality of life) for GBM patients on active treatment.

Inclusion: histologically confirmed diagnosis of either primary or secondary GBM; received any dose of DEX; Karnofsky Performance Status (KPS) >70; English fluency; physician approval; willingness to travel to Halifax to participate.

Exclusion: unstable or symptomatic cardiac or pulmonary disease, injury or co-morbid disease that precludes ability to safely exercise; uncontrolled seizures associated with impaired awareness; significant cognitive limitations.

ClinicalTrials.gov NCT05116137